start-ver=1.4
cd-journal=joma
no-vol=53
cd-vols=
no-issue=1
article-no=
start-page=9
end-page=19
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2013
dt-pub=201306
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Evaluation of Immunohistochemical Markers and Thymic Cortical Microenvironmental Cells in Distinguishing Thymic Carcinoma from Type B3 Thymoma or Lung Squamous Cell Carcinoma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Thymic carcinoma (TC) is often very difficult to distinguish from type B3 thymoma and lung squamous cell carcinoma (L-SCC) involving the anterior mediastinum. The present study evaluated the usefulness of immunohistochemical markers including c-Kit, CD5, glucose transporter-1 (GLUT-1), claudin-1 (CLDN-1), thymoproteasome ƒÀ5t, p53 and Ki-67 (MIB-1) and thymic cortical environmental marker cells, cortical thymocytes (c-Thy) and thymic cortical dendritic macrophages (TCDMs) in distinguishing thymic carcinoma (TC) from type B3 thymoma or lung squamous cell carcinoma (L-SCC) using 17 cases of type B3 thymoma, 18 cases of TC and 12 cases of L-SCC. The results indicated that c-Kit and CD5 are very useful markers for TC, while GLUT-1, CLDN-1, p53 and Ki-67 are not. Thymic cortical microenvironmental marker cells, especially TCDMs, and thymic cortical epithelial cell-marker ƒÀ5t are also useful for distinguishing TC from type B3 thymoma. Although none of these markers are adequate for making a distinction when used alone, the plural use of c-Kit, CD5, ƒÀ5t thymic cortical environmental marker cells, c-Thys and TCDMs may therefore lead to a correct distinction between TC and type B3 thymoma or L-SCC. [J Clin Exp Hematop 53(1) : 9-19, 2013]
en-copyright=
kn-copyright=

en-aut-name=HayashiAtsushi
en-aut-sei=Hayashi
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FumonTakumi
en-aut-sei=Fumon
en-aut-mei=Takumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MikiYukari
en-aut-sei=Miki
en-aut-mei=Yukari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SatoHiaki
en-aut-sei=Sato
en-aut-mei=Hiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YoshinoTadashi
en-aut-sei=Yoshino
en-aut-mei=Tadashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TakahashiKiyoshi
en-aut-sei=Takahashi
en-aut-mei=Kiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=
kn-affil=Department of Medical Technology, Graduate School of Health Science, Okayama University

affil-num=2
en-affil=
kn-affil=Department of Medical Technology, Graduate School of Health Science, Okayama University

affil-num=3
en-affil=
kn-affil=Department of Medical Technology, Graduate School of Health Science, Okayama University

affil-num=4
en-affil=
kn-affil=Department of Medical Technology, Graduate School of Health Science, Okayama University

affil-num=5
en-affil=
kn-affil=Department of Pathology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University

affil-num=6
en-affil=
kn-affil=Department of Medical Technology, Graduate School of Health Science, Okayama University
en-keyword=thymic carcinoma
kn-keyword=thymic carcinoma
en-keyword=type B3 thymoma
kn-keyword=type B3 thymoma
en-keyword=lung squamous cell carcinoma
kn-keyword=lung squamous cell carcinoma
en-keyword=immunohistochemical distinction
kn-keyword=immunohistochemical distinction
END